Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Eli Lilly (NY:LLY)

1,079.41 -25.59 (-2.32%)
Streaming Delayed Price Updated: 2:18 PM EDT, Jun 1, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Eli Lilly

< Previous 1 2 3 4 5 6 7 8 9
...
99 100 Next >
News headline image
Watch Out, Eli Lilly and Novo Nordisk: Viking Therapeutics' Pill Could Crash the Weight-Loss Party ↗
This dark horse in the weight loss drug race is worth keeping on your watch list. 
Via The Motley Fool
News headline image
Eli Lilly Stock: Next Stop $2,000? ↗
The company is riding an incredible tailwind. 
Via The Motley Fool
News headline image
Supreme Court Rejects Eli Lilly Appeal In Medicaid Fraud Case ↗
Supreme Court lets stand $194 million Medicaid fraud award against Eli Lilly in whistleblower case challenging False Claims Act. 
Via Benzinga
Topics Fraud Whistleblower
News headline image
3 Deeply Undervalued Stocks You Can Buy for Less Than $100 Right Now ↗
These stocks could look like steals in a few years. 
Via The Motley Fool
Topics Intellectual Property
LLY: Eli Lilly & Co. Passes the Affordable Growth (GARP) Screen with Strong Momentum and Fair Valuation ↗
Via Chartmill
Eli Lilly & Co. (NYSE:LLY) Passes the "Little Book That Makes You Rich" Growth Screen ↗
Via Chartmill
News headline image
Could Eli Lilly's Next Weight Loss Drug Waylay Wegovy -- and Even Zap Zepbound? ↗
Promising clinical trial data suggests big opportunity with Eli Lilly's retatrutide GLP-1 candidate. 
Via The Motley Fool
News headline image
Is Kailera Therapeutics a Buy After Its Sizzling IPO? ↗
There's a new challenger to the more established players in the weight-loss drug space. 
Via The Motley Fool
Topics Initial Public Offering
News headline image
If You Invested $1000 In Eli Lilly Stock 20 Years Ago, You Would Have This Much Today ↗
 
Via Benzinga
News headline image
Buy, Sell, or Hold Novo Nordisk at $46? ↗
Can Novo Nordisk thrive under intense competitive pressures? 
Via The Motley Fool
News headline image
My Top 3 Healthcare Stocks for May 2026 ↗
Healthcare is booming, and these three companies stand to profit handsomely from growing demand for medications and surgeries. 
Via The Motley Fool
News headline image
This Hot Weight-Loss Drug Stock May Have a Surprise Challenger
The race to dominate the weight-loss drug market is heating up, and investors should start watching this one smaller player closely. 
Via Barchart.com
Topics Earnings Lawsuit
News headline image
Should Eli Lilly Investors Worry About Its Newest Rival -- From Within? ↗
Eli Lilly is dominating one of the biggest growth markets in healthcare: the weight loss drug market. 
Via The Motley Fool
News headline image
Amphastar Pharmaceuticals Tackles BAQSIMI Discount Pressure, Keeps Sales Outlook ↗
Amphastar Pharmaceuticals (NASDAQ:AMPH) executives said the company is taking steps to address rebate and discounting pressure on BAQSIMI while maintaining its full-year revenue outlook, according to... 
Via MarketBeat
News headline image
This Weight-Loss Drug Challenger Could Follow Eli Lilly's Playbook: Analyst ↗
William Blair gives Kailera Therapeutics ($KLRA) an Outperform rating. Learn why analysts see a competitive edge in their GLP-1 assets. 
Via Benzinga
News headline image
Is Novo Nordisk's Rebound for Real--or Just a Head Fake? ↗
The worst might be in the rearview mirror. 
Via The Motley Fool
News headline image
Eli Lilly Says Newly Approved Foundayo, Lower-Dose Zepbound Help Sustain Weight Loss ↗
Eli Lilly data shows patients maintain weight loss with Foundayo or lower-dose Zepbound after switching from injectable therapies. 
Via Benzinga
News headline image
1 of Wall Street’s Favorite Stock to Target This Week and 2 We Avoid
The stocks in this article have caught Wall Street’s attention in a big way, with price targets implying returns above 20%. But investors should take these f... 
Via StockStory
Topics Retirement
News headline image
Q1 Earnings Roundup: Amphastar Pharmaceuticals (NASDAQ:AMPH) And The Rest Of The Pharmaceuticals Segment
As the craze of earnings season draws to a close, here’s a look back at some of the most exciting (and some less so) results from Q1. Today, we are looking a... 
Via StockStory
Topics Artificial Intelligence Intellectual Property
News headline image
Eli Lilly (LLY) Stock Trades Up, Here Is Why
What Happened? Shares of global pharmaceutical company Eli Lilly (NYSE:LLY) jumped 2.4% in the afternoon session after the stock continued to rally as the co... 
Via StockStory
News headline image
Meet The New IPO Trying To Take On Eli Lilly And Novo Nordisk In Obesity ↗
Analysts initiated covered Tuesday of IPO stock, a potential competitor to Lilly and Novo in obesity. 
Via Investor's Business Daily
Topics Initial Public Offering
News headline image
Why Hims & Hers Health Stock Just Crashed ↗
Hims & Hers is unshaken by its earnings miss, with management promising even faster sales growth this year. 
Via The Motley Fool
Topics Earnings Lawsuit
News headline image
The 3 Best S&P 500 Stocks to Buy Now ↗
These growth stocks are benefiting from major tailwinds across cloud computing, digital payments, and healthcare. 
Via The Motley Fool
Topics Artificial Intelligence Credit Cards Economy
News headline image
Peptide Wellness Market Could Near $300 Billion as Consumer Demand Accelerates
EQNX::TICKER_START (OTCQB:PNGAF),(CSE:BPC),(NYSE:PFE),(NYSE:NVO),(NYSE:HIMS),(NYSE:LLY) EQNX::TICKER_END 
Via FinancialNewsMedia
News headline image
Peptide Wellness Market Could Near $300 Billion as Consumer Demand Accelerates
Next-generation wellness platforms targeting longevity, metabolism, and performance continue gaining momentum in one of healthcare’s fastest-growing sectors 
From MarketNewsUpdates.com
Via GlobeNewswire
News headline image
Income or Growth: Which Healthcare Stock Fits Your Portfolio Right Now? ↗
It's important to look beyond near-term volatility. 
Via The Motley Fool
Topics Economy Retirement Stocks
BioMedNewsBreaks — SureNano Science Ltd. (CSE: SURE) (OTCQB: SURNF) Advances Next-Generation GLP-1 Candidate as Obesity Drug Market Expands Rapidly
Via Investor Brand Network
The Next Generation of the GLP-1 Revolution Is Already Underway
Via Investor Brand Network
News headline image
The Next Generation of the GLP-1 Revolution Is Already Underway
From BioMedWire
Via GlobeNewswire
News headline image
Is This News From Novo Nordisk a Warning for Eli Lilly Shareholders? ↗
The weight loss drug market is on track to reach almost $100 billion. 
Via The Motley Fool
< Previous 1 2 3 4 5 6 7 8 9
...
99 100 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.